Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Management and Challenges of Inflammatory Eye Diseases
share announcement

Management and Challenges of Inflammatory Eye Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (1 March 2024) | Viewed by 1087

Special Issue Editor

Dr. Evaggelia K. Aissopou

E-Mail Website
Guest Editor
Department of Ophthalmology, Macula Center, 10682 Athens, Greece
Interests: retinal imaging; retinal diseases; uveitis; retinal microcirculation; retinal vessel calibers

Special Issue Information

Dear Colleagues,

Inflammatory eye diseases encompass a diverse group of conditions that affect various structures of the eye, such as the uvea, retina, sclera and surrounding tissues, not only in adults, but also in children. The history of managing these diseases is marked by a gradual evolution in diagnostic techniques and treatment modalities that have led to a deeper understanding of the complex immunological processes underlying inflammatory eye diseases.

Challenges such as refractory cases, long-term treatment side effects and individual variability in response to therapies remain major obstacles to clinical practice. The primary goal of this Special Issue is to provide a comprehensive overview of diagnostic and treatment management in order to facilitate the development of personalized approaches to patient care, improving clinical outcomes and enhancing the quality of life of these patients.

Advancements in immunology, the identification of novel biomarkers and state-of-the-art imaging techniques have enabled earlier and more accurate disease detection, facilitating prompt intervention. We invite researchers, clinicians and experts in the field to contribute original research articles, reviews and short communications that review the existing challenges and highlight the latest developments of diagnostic and therapeutic approaches to inflammatory eye diseases.

Dr. Evaggelia K. Aissopou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory eye diseases
  • uveitis
  • scleritis
  • keratitis
  • diagnostic techniques
  • biomarkers
  • targeted therapeutics
  • visual impairment

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 969 KiB  
Article
Identifying and Exploring the Impact Factors for Intraocular Pressure Prediction in Myopic Children with Atropine Control Utilizing Multivariate Adaptive Regression Splines
by Tzu-En Wu, Jun-Wei Chen, Tzu-Chi Liu, Chieh-Han Yu, Mao-Jhen Jhou and Chi-Jie Lu
J. Pers. Med. 2024, 14(1), 125; https://doi.org/10.3390/jpm14010125 - 22 Jan 2024
Cited by 1 | Viewed by 853
Abstract
Purpose: The treatment of childhood myopia often involves the use of topical atropine, which has been demonstrated to be effective in decelerating the progression of myopia. It is crucial to monitor intraocular pressure (IOP) to ensure the safety of topical atropine. This study [...] Read more.
Purpose: The treatment of childhood myopia often involves the use of topical atropine, which has been demonstrated to be effective in decelerating the progression of myopia. It is crucial to monitor intraocular pressure (IOP) to ensure the safety of topical atropine. This study aims to identify the optimal machine learning IOP-monitoring module and establish a precise baseline IOP as a clinical safety reference for atropine medication. Methods: Data from 1545 eyes of 1171 children receiving atropine for myopia were retrospectively analyzed. Nineteen variables including patient demographics, medical history, refractive error, and IOP measurements were considered. The data were analyzed using a multivariate adaptive regression spline (MARS) model to analyze the impact of different factors on the End IOP. Results: The MARS model identified age, baseline IOP, End Spherical, duration of previous atropine treatment, and duration of current atropine treatment as the five most significant factors influencing the End IOP. The outcomes revealed that the baseline IOP had the most significant effect on final IOP, exhibiting a notable knot at 14 mmHg. When the baseline IOP was equal to or exceeded 14 mmHg, there was a positive correlation between atropine use and End IOP, suggesting that atropine may increase the End IOP in children with a baseline IOP greater than 14 mmHg. Conclusions: MARS model demonstrates a better ability to capture nonlinearity than classic multiple linear regression for predicting End IOP. It is crucial to acknowledge that administrating atropine may elevate intraocular pressure when the baseline IOP exceeds 14 mmHg. These findings offer valuable insights into factors affecting IOP in children undergoing atropine treatment for myopia, enabling clinicians to make informed decisions regarding treatment options. Full article
(This article belongs to the Special Issue Management and Challenges of Inflammatory Eye Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop